Biblio
“Linking Air Pollution Exposure to Blood-Based Metabolic Features in a Community-Based Aging Cohort with and without Dementia.”, J Alzheimers Dis, vol. 96, no. 3, pp. 1025-1040, 2023.
, “Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost.”, J Alzheimers Dis, vol. 49, no. 2, pp. 277-85, 2016.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.”, Lancet Neurol, vol. 10, no. 2, pp. 187-98, 2011.
, “Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 451-61, 2016.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Low Prevalence of Cancer in Patients with Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 62, no. 2, pp. 789-794, 2018.
, “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
, “Memory consolidation, temporal and parietal atrophy, and metabolism in amyloid-β positive and negative mild cognitive impairment.”, J Alzheimers Dis, vol. 102, no. 3, pp. 778-791, 2024.
, “Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1205-15, 2016.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “Spiritual Fitness: A New Dimension in Alzheimer's Disease Prevention.”, J Alzheimers Dis, vol. 80, no. 2, pp. 505-519, 2021.
, “Alteration of Gut Microbiota in Alzheimer's Disease and Their Relation to the Cognitive Impairment.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1103-1114, 2022.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
, “Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 405-15, 2016.
, “18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 57, no. 3, pp. 711-716, 2017.
, “Distinctive Resting State Network Disruptions Among Alzheimer's Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients.”, J Alzheimers Dis, vol. 50, no. 3, pp. 709-18, 2016.
, “The Impact of APOE ɛ4 in Alzheimer's Disease Differs According to Age.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1377-1385, 2018.
, “Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.”, J Alzheimers Dis, vol. 87, no. 1, pp. 83-100, 2022.
, “Discovering New Genes in the Pathways of Common Sporadic Neurodegenerative Diseases: A Bioinformatics Approach.”, J Alzheimers Dis, vol. 51, no. 1, pp. 293-312, 2016.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1057-68, 2016.
, “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
,